Oral mucosal carcinogenesis in hamsters: inhibition by vitamin E

Print
Published on Wednesday, 10 January 2018

Abstract

Eighty young adult male and female Syrian golden hamsters (Mesocricetus auratus) were divided into 4 equal experimental groups.

In group I animals the left buccal pouch was painted three times weekly with a 0.5% solution of 7,12-dimethylbenz[a]anthracene (DMBA) in heavy mineral oil.

In group 2 animals the left buccal pouch was similarly painted with DMBA, but the animals also received orally 10 mg vitamin E (dl-alpha-tocopherol) in peanut oil twice weekly on alternate days with DMBA painting.

Group 1 animals received a similar amount of peanut oil vehicle, group 3 animals received only vitamin E (vitamin E controls) in peanut oil, and group 4 animals served as untreated controls receiving only peanut oil.

Four animals in each group (2 males and 2 females) were killed at 8, 10, 12, 14, and 16 weeks. Buccal pouches were photographed and excised, and tumors were noted and measured in the left buccal pouches.

In group 2 animals receiving vitamin E, tumor formation was significantly delayed, so that by 14-16 weeks there were fewer tumors and their average size was smaller than that of tumors in group 1 animals that were painted with DMBA but received no vitamin E supplement. In group 2 there was also less invasion of underlying tissues and less surface necrosis.

 

 

About this publication.

 

See also:

- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;

- All-Trans-Retinoic Acid (ATRA - analogues and/or derivatives);

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- The Di Bella Method (A Fixed Part - Alpha tocopheryl acetate/Vitamin E);

- Congenital fibrosarcoma in complete remission with Somatostatin, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow Up;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis;

- Chronic Lymphocytic Leukemia: Long-Lasting Remission with Combination of Cyclophosphamide, Somatostatin, Bromocriptine, Retinoids, Melatonin, and ACTH;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.